Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18758038 | Trispecific T cell Engagers | June 2024 | December 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18628224 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT | April 2024 | December 2025 | Abandon | 20 | 2 | 0 | No | No |
| 18622066 | Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors | March 2024 | October 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18600481 | BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND HER2, AND METHODS OF USE THEREOF | March 2024 | December 2025 | Allow | 21 | 1 | 1 | No | No |
| 18545890 | CLAUDIN 4 AND CLAUDIN 9 ANTIBODIES AND METHODS OF TREATING CANCER | December 2023 | September 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18481291 | METHODS OF TREATING HER2-POSITIVE CANCER | October 2023 | June 2024 | Abandon | 8 | 0 | 0 | No | No |
| 18452972 | METHODS OF TREATING CANCER | August 2023 | May 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18323898 | COMPOSITIONS AND METHODS FOR INHIBITING OR SCREENING FOR CD8 AND METHODS AND ASSAYS FOR DETECTING CD8 IN CELLS | May 2023 | March 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18181661 | IMMUNOSTIMULATORY AGONISTIC ANTIBODIES FOR USE IN TREATING CANCER | March 2023 | October 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18160202 | NIR-CONJUGATED TUMOR-SPECIFIC ANTIBODIES AND USES THEREOF | January 2023 | August 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18154295 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER METASTASIS | January 2023 | November 2024 | Abandon | 22 | 1 | 1 | No | No |
| 18153286 | MODIFIED ANTIBODY-ALBUMIN NANOPARTICLE COMPLEXES FOR CANCER TREATMENT | January 2023 | October 2025 | Abandon | 33 | 3 | 1 | No | No |
| 18090570 | COMBINATION THERAPY WITH ANTI-IL-8 ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATING CANCER | December 2022 | June 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17991775 | NOVEL ANTIBODIES AND METHODS FOR MAKING AND USING THE SAME | November 2022 | October 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 18056711 | HUMAN PD-L1 ANTIBODIES AND METHODS OF USE THEREFOR | November 2022 | February 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 18054347 | ENZYME-MEDIATED DEPLETION OF ADENOSINE AND/OR METHYLTHIOADENOSINE | November 2022 | January 2025 | Abandon | 26 | 2 | 1 | No | No |
| 17975508 | ANTIBODIES SPECIFIC FOR GUCY2C AND USES THEREOF | October 2022 | December 2024 | Allow | 25 | 1 | 1 | No | No |
| 17917513 | Monoclonal Antibodies and Antigen Binding Fragments Thereof for Suppressing CD73 Immune Checkpoint and Uses Thereof | October 2022 | March 2026 | Allow | 41 | 1 | 1 | Yes | No |
| 17932986 | COMBINATION THERAPY | September 2022 | August 2023 | Abandon | 11 | 0 | 1 | No | No |
| 17823640 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH ACTIVATION OF THE MAPK PATHWAY | August 2022 | March 2025 | Abandon | 31 | 3 | 1 | No | No |
| 17820624 | RECOMBINANT BIFUNCTIONAL PROTEIN TARGETING CD47 AND HER2 | August 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17818907 | INHIBITORS OF EPHRIN B1 FOR TUMOR TREATMENT | August 2022 | March 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17883158 | BISPECIFIC BINDING MOLECULES THAT ARE CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS, AND USES THEREOF | August 2022 | November 2023 | Allow | 15 | 1 | 0 | No | No |
| 17815514 | ANTI-CD46 ANTIBODIES AND METHODS OF USE | July 2022 | November 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17859078 | PEPTIDE-LIPOSOME COMPLEX FOR MULTIVALENT CROSSLINKING WITH PD-L1 AND COMPOSITION INCLUDING THE SAME | July 2022 | February 2026 | Abandon | 43 | 2 | 1 | No | No |
| 17853606 | Novel Monoclonal Antibodies to Programmed DEATH (PD-1) | June 2022 | January 2024 | Abandon | 18 | 1 | 1 | No | No |
| 17808964 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | June 2022 | March 2026 | Abandon | 45 | 0 | 1 | No | No |
| 17786717 | COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17830817 | METHODS OF TREATING CANCER WITH AN ANTI-CD39 ANTIBODY AND PEMBROLIZUMAB | June 2022 | July 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17747886 | USES OF ANTI-ICOS ANTIBODIES | May 2022 | February 2026 | Abandon | 45 | 4 | 1 | No | No |
| 17738191 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | May 2022 | November 2023 | Allow | 18 | 2 | 1 | No | No |
| 17719609 | CLAUDIN 4 AND CLAUDIN 9 ANTIBODIES AND METHODS OF TREATING CANCER | April 2022 | September 2023 | Allow | 17 | 1 | 1 | Yes | No |
| 17718888 | METHODS OF TREATING CANCER | April 2022 | October 2023 | Abandon | 18 | 1 | 1 | No | No |
| 17768290 | METHODS OF TREATING HER2 POSITIVE BREAST CANCER WITH TUCATINIB IN COMBINATION WITH CAPECITABINE AND TRASTUZUMAB | April 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17768455 | COMBINATION THERAPY FOR TREATMENT OF CANCERS | April 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17714724 | METHODS OF TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA USING TELISOTUZUMAB VEDOTIN | April 2022 | May 2025 | Allow | 37 | 4 | 0 | Yes | Yes |
| 17766450 | FUSION PROTEIN, AND PREPARATION METHOD AND USE THEREOF | April 2022 | September 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17656698 | AFFINITY MATURATED TAG72 SPECIFIC SINGLE CHAIN ANTIBODIES | March 2022 | January 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17692006 | METHODS OF TREATING CANCER | March 2022 | October 2023 | Abandon | 19 | 1 | 1 | No | No |
| 17691645 | DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 (HER3) MONOCLONAL ANTIBODIES TO TREAT TUMORS ASSOCIATED WITH NEUREGULIN 1 (NRG1) GENE FUSIONS | March 2022 | August 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17686565 | THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER | March 2022 | July 2025 | Abandon | 40 | 2 | 0 | No | No |
| 17652709 | ANTI-PD-1 ANTIBODIES FOR TREATMENT OF LUNG CANCER | February 2022 | October 2023 | Allow | 20 | 1 | 1 | Yes | No |
| 17670413 | METHODS OF TREATING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS AND ADDITIONAL THERAPEUTIC AGENTS | February 2022 | June 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17667901 | CREBBP RELATED CANCER THERAPY | February 2022 | April 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17666424 | METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES | February 2022 | February 2025 | Abandon | 36 | 2 | 1 | No | No |
| 17583521 | ANTI-PD-L1 ANTIBODIES AND VARIANTS | January 2022 | November 2022 | Allow | 10 | 0 | 0 | Yes | No |
| 17629139 | INHIBITORS OF CHI3L1 AND THEIR USES | January 2022 | February 2026 | Abandon | 49 | 2 | 1 | No | No |
| 17575246 | NEUTRALIZING ANTI-SARS-COV-2 ANTIBODIES | January 2022 | April 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17571430 | METHODS OF CANCER TREATMENT USING TUMOR ANTIGEN-SPECIFIC T CELLS | January 2022 | June 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17563866 | METHODS FOR TREATING CANCERS WITH MODIFIED PBMCS | December 2021 | December 2025 | Abandon | 47 | 4 | 1 | No | No |
| 17620395 | COMPOSITIONS AND METHODS TARGETING THE NUCLEOTIDE FREE STATE OF RAS TO BLOCK ONCOGENIC SIGNALING AND TRANSFORMATION | December 2021 | October 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17554682 | COMPOSITIONS AND METHODS FOR EDITING BETA-GLOBIN FOR TREATMENT OF HEMAGLOBINOPATHIES | December 2021 | August 2025 | Allow | 44 | 3 | 1 | Yes | No |
| 17550276 | Compositions and Methods for the Treatment of Cancer (Anti-ICOS Antibody Dosing) | December 2021 | June 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17615863 | ANTI-PSGL-1 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF | December 2021 | October 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17535004 | AMHRII-BINDING COMPOUNDS FOR PREVENTING OR TREATING CANCERS | November 2021 | January 2025 | Abandon | 38 | 4 | 1 | No | No |
| 17525898 | Methods and agents to treat tumor cells and cancer | November 2021 | May 2024 | Abandon | 30 | 2 | 1 | No | No |
| 17524049 | METHODS AND COMPOSITIONS COMPRISING A KRASG12C INHIBITOR AND A PD-L1 BINDING ANTAGONIST FOR TREATING LUNG CANCER | November 2021 | August 2024 | Allow | 34 | 3 | 1 | No | No |
| 17609641 | GLYCOPEPTIDE VACCINE | November 2021 | September 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17519327 | Combinations of Cabozantinib and Atezolizumab to Treat Cancer | November 2021 | November 2024 | Abandon | 36 | 3 | 0 | No | No |
| 17518272 | MODULATING GABARAP TO MODULATE IMMUNOGENIC CELL DEATH | November 2021 | February 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17509028 | Methods, agents and compositions as in situ vaccine for cancer cell and tumor treatment | October 2021 | March 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17605331 | SYSTEMS AND METHODS FOR MODULATING A CELL PHENOTYPE | October 2021 | June 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17599179 | CANCER BIOMARKERS FOR DURABLE CLINICAL BENEFIT | September 2021 | June 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17442640 | SUBSTANCE INTERACTING WITH C TERMINAL FRAGMENT OF THE STIM1 FRACTION LOCALIZED TO THE PLASMA MEMBRANE OF THE CELLS, FOR ITS USE IN THE TREATMENT OF CANCERS, AND IN SCREENING AND DIAGNOSTIC METHODS | September 2021 | November 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17438545 | TARGETING REGULATORY B CELLS AND THEIR REGULATORS FOR CANCER IMMUNOTHERAPY | September 2021 | December 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17468115 | LASOFOXIFENE TREATMENT OF VVA AND OSTEOPOROSIS IN SURVIVORS OF BREAST CANCER AND OTHER MALIGNANCIES | September 2021 | June 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17435561 | MRNA VACCINE | September 2021 | December 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17407404 | RECOMBINANT BIFUNCTIONAL PROTEIN TARGETING CD47 AND HER2 | August 2021 | December 2022 | Abandon | 15 | 2 | 0 | Yes | No |
| 17404717 | PANCREATIC CANCER DETECTION METHOD AND PANCREATIC CANCER DETECTION KIT | August 2021 | September 2023 | Allow | 25 | 1 | 1 | Yes | No |
| 17427545 | ANTIBODY AND FUNCTIONAL FRAGMENT THEREOF | July 2021 | March 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17387223 | ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAME | July 2021 | July 2025 | Allow | 47 | 3 | 1 | Yes | No |
| 17424964 | BINDER AGAINST PROGRAMMED DEATH-LIGAND AND APPLICATION THEREOF | July 2021 | February 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17357380 | Combination Therapy for Cancer | June 2021 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17413260 | ANTIBODY-TNF alpha FUSION PROTEIN AND ITS PREPARATION AND APPLICATIONS | June 2021 | February 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17312019 | IMPROVED ANTIBODY-OLIGONUCLEOTIDE CONJUGATE | June 2021 | April 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17338149 | ANTI-CD70 ANTIBODIES AND USES THEREOF | June 2021 | April 2024 | Allow | 35 | 2 | 1 | No | No |
| 17329075 | [6R]-MTHF - an efficient folate alternative in 5-fluorouracil based chemotherapy | May 2021 | September 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17320996 | Immune Monitoring of Neuro-Inflammatory Amyotrophic Lateral Sclerosis (ALS) | May 2021 | September 2025 | Allow | 52 | 2 | 1 | No | No |
| 17294345 | METHODS OF SELECTING FUNCTIONAL INTERFACE MIMICS, AND COMPOSITIONS THEREOF | May 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17294008 | AGONISTIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES | May 2021 | May 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17291303 | FGL2 NEUTRALING CELL THERAPY AND METHODS OF USE THEREOF | May 2021 | February 2026 | Abandon | 58 | 2 | 1 | Yes | No |
| 17290180 | ANTI-HUMAN Fn14 ANTIBODY | April 2021 | September 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17289389 | METHODS OF TREATING CANCER | April 2021 | April 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17289204 | CRISPR/CAS12F ENZYME AND SYSTEM | April 2021 | March 2026 | Allow | 59 | 4 | 1 | Yes | No |
| 17238599 | ACTIVITY SENSOR CONTROLS | April 2021 | December 2024 | Abandon | 44 | 2 | 1 | No | No |
| 17285470 | MONOCLONAL ANTIBODIES AGAINST HUMAN DICKKOPF3 AND USES THEREOF | April 2021 | December 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 17284119 | ANTI-MERTK ANTIBODIES FOR TREATING CANCER | April 2021 | February 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17281724 | PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD37 ANTIBODIES | March 2021 | October 2025 | Abandon | 54 | 2 | 0 | No | No |
| 17275974 | RECOMBINANT POXVIRUSES FOR CANCER IMMUNOTHERAPY | March 2021 | October 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17187511 | BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND HER2, AND METHODS OF USE THEREOF | February 2021 | December 2023 | Allow | 33 | 2 | 1 | Yes | No |
| 17271500 | PLK1 TARGET PHOSPHORYLATION STATUS AND TREATMENT OF CANCER WITH PLK1 INHIBITORS | February 2021 | February 2026 | Allow | 59 | 4 | 0 | Yes | No |
| 17184360 | MOLECULAR BIOMARKERS AND TARGETS FOR FUCHES' ENDOTHELIAL CORNEAL DYSTROPHY AND GLAUCOMA | February 2021 | December 2025 | Allow | 58 | 6 | 1 | Yes | No |
| 17266883 | CANCER TREATMENT WITH AN ANTIBODY | February 2021 | October 2023 | Allow | 32 | 1 | 0 | Yes | No |
| 17265755 | EPITOPE OF EPB41L5, AND MONOCLONAL ANTIBODY | February 2021 | March 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17164696 | Trispecific T cell Engagers | February 2021 | March 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 17154889 | COMPOSITIONS AND METHODS FOR INHIBITING OR SCREENING FOR CD8 AND METHODS AND ASSAYS FOR DETECTING CD8 IN CELLS | January 2021 | August 2023 | Abandon | 31 | 1 | 1 | No | No |
| 17254433 | COMPOSITIONS AND METHODS FOR PROTEIN LABELING, MODIFICATION, ANALYSIS, AND TARGETED DELIVERY | December 2020 | September 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17252035 | COMPOSITION FOR DIAGNOSIS OF BONE METASTASIS OF CANCER AND KIT COMPRISING SAME | December 2020 | March 2025 | Abandon | 51 | 3 | 0 | No | No |
| 16972404 | INHIBITORS OF SHP2 | December 2020 | June 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17059995 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING CD300C EXPRESSION INHIBITOR OR ACTIVITY INHIBITOR | November 2020 | November 2024 | Abandon | 48 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LU, CHENG.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LU, CHENG works in Art Unit 1642 and has examined 174 patent applications in our dataset. With an allowance rate of 56.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner LU, CHENG's allowance rate of 56.9% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LU, CHENG receive 1.95 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LU, CHENG is 39 months. This places the examiner in the 25% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +69.5% benefit to allowance rate for applications examined by LU, CHENG. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.1% of applications are subsequently allowed. This success rate is in the 46% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 57.8% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 85.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 18.2% of allowed cases (in the 93% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.